An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens
Underscores ozuriftamab vedotin's activity in a high unmet need SCCHN patient population
The conditionally binding ADC targeting ROR2 was notably well tolerated
The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented a poster of promising Phase 2 trial data at the European Society for Medical Oncology (ESMO) Annual Meeting. The poster presentation entitled, "Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck," reported multiple confirmed responses among heavily pretreated patients who tolerated treatment well. The Company's novel, conditionally active anti-ROR2-ADC was recently granted FDA Fast Track Designation for treatment of patients with recurrent or metastatic (R/M) SCCHN.
